Chicago Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Chicago Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.41M	Sell	12,119 -26	-0.2%	-$12.1K	0.15%	81
2025 Q4	$5.51M	Sell	12,145 -679	-5%	-$293K	0.14%	85
2025 Q3	$5.02M	Sell	12,824 -51	-0.4%	-$21.3K	0.12%	87
2025 Q2	$5.73M	Buy	12,875 +469	+4%	+$216K	0.14%	77
2025 Q1	$6.01M	Buy	12,406 +188	+2%	+$87.6K	0.17%	80
2024 Q4	$4.92M	Sell	12,218 -74	-0.6%	-$34.3K	0.13%	85
2024 Q3	$5.72M	Sell	12,292 -377	-3%	-$181K	0.16%	78
2024 Q2	$5.94M	Buy	12,669 +282	+2%	+$122K	0.18%	78
2024 Q1	$5.18M	Buy	12,387 +447	+4%	+$189K	0.16%	76
2023 Q4	$4.86M	Buy	+11,940	New	+$4.41M	0.17%	75

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Chicago Capital's VRTX Position: Q1 2026 in Review

Chicago Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 0.21% in Q1 2026, selling an estimated $12.1K and leaving 12,119 shares worth $5.41M. The position accounts for 0.15% of the portfolio, ranked #81.

Chicago Capital first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $6.01M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Chicago Capital held 12,119 shares of Vertex Pharmaceuticals worth $5.41M as of Q1 2026.
Chicago Capital sold 26 Vertex Pharmaceuticals shares in Q1 2026, an estimated $12.1K.
Vertex Pharmaceuticals made up 0.15% of Chicago Capital's portfolio in Q1 2026, its #81 holding.
Chicago Capital first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Chicago Capital's Vertex Pharmaceuticals position peaked at $6.01M in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Chicago Capital's 13F filing for Q1 2026, filed 24 Apr 2026.